GKL-006

· Beijing Gene Key Life Technology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GKL-006, covering 2025-10-07 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma [Phase 2]